

4th meeting on
Innovative immunotherapies for Lymphoid Malignancies
Milano, Rosa Grand Hotel, January 22-23, 2026

PROGRAM

First DAY

09:00 am Welcome and introduction

SESSION I – The evolving role of checkpoint inhibitors in lymphomas

09:15 am In Hodgkin lymphoma

09:40 am In Non-Hodgkin lymphoma

10:05 am Mechanisms of resistance to checkpoint inhibitors, novel checkpoints, and novel combinations

10:30 am Coffee break

SESSION II – Bispecific T-cell engagers in lymphoma

10:45 am Clinical results of bispecific antibodies in aggressive NHL: what's next?

11:10 am Clinical results of bispecific antibodies in indolent NHL: what's next?

11:35 am New bispecifics and ... trispecifics

SESSION III – Bispecific T-cell engagers in myeloma

12:00 pm Clinical results in multiple myeloma: BCMA, what's next?

12:25 pm Clinical results in multiple myeloma: GPRC5D, FcRH5, and novel targets

12:50 pm Novel targets

01:10 pm Lunch

SESSION IV – Resistance to bispecific T-cell engagers

02:30 pm In Non-Hodgkin lymphomas

02:55 pm In multiple myeloma

DEBATE

03:20 pm Is there a role for allogeneic transplant after bispecifics and CAR-T in NHL?

03:40 pm Panel discussion

SESSION V – Immunotherapy "MADE in ITALY"

03:50 pm Humanitas: Recent Advances in Modulation of T Cell Function Against Cancer

04:10 pm Innovative Immunotherapies at "Seràgnoli" Insitute University of Bologna

04:30 pm IEO's Latest Contributions in Cellular Therapies

04:50 pm San Raffaele: Cutting-Edge CAR-T Developments

05:10 pm Coffee break

05:25 pm New Efforts at Ospedale Bambin Gesù Roma

05:45 pm New Efforts in Bergamo and Monza

06:05 pm New targets and CART for lymphoma developed at the University of Perugia

06:25 pm Clinical-translational results from the Istituto Nazionale Tumori in Milano

Second DAY

SESSION VI – Clinical updates in CAR-T therapies

- 08:30 am Clinical results CAR-T for DLBCL: What's next?
- 08:55 am Clinical results CAR-T for mantle cell lymphoma: What's next?
- 09:20 am Clinical results CAR-T for follicular lymphoma: What's next?
- 09:45 am Clinical results CAR-T for T-cell lymphomas: Are we catching up?
- 10:10 am Clinical results CAR-T for Hodgkin lymphoma: Are we catching up?

10:35 am Coffee break

SESSION VII – Advances in Cell Therapies

- 10:50 am New Effector Cells for immunotherapy: NK, NKT, gd T cells, and macrophages
- 11:15 pm In vivo CAR-T therapies

SESSION VIII – T-cell Based Therapy Toxicities

- 11:40 am CAR-T toxicities in NHL and MM: Non-relapse mortality, infections, secondary cancers and delayed neurotoxicities
- 12:05 pm Bispecific antibodies' toxicities in NHL and MM
- 12:30 pm Strategies to reduce early and late CART toxicities

12:55 pm Lunch

SESSION IX – CAR-T resistance and novel opportunities

- 02:00 pm Resistance Mechanisms of CAR-T Cells in Lymphoma: Clinical Evidence
- 02:25 pm Laboratory-Based Mechanisms of CAR-T Resistance
- 02:50 pm Patient Selection, Bridging Therapy, and Lymphodepletion Techniques
- 03:15 pm Allogeneic CAR-T: what is the right setting?
- 03:40 pm Microbiome, diet and host factors: how do they affect T-cell immunotherapies
- 04:05 pm Conclusions and arrivederci!